Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy, a useful tool for assessment of cardioprotective agents

Anna Potáčová, Michaela Adamcová, H. Čajnáková, L. Hrbatová, Martin Štěrba, Olga Popelová, Tomáš Šimůnek, Přemysl Poňka, Vladimír Geršl

. 2007 ; 56 (2) : 251-254.

Jazyk angličtina Země Česko

Perzistentní odkaz   https://www.medvik.cz/link/bmc07502303

The aim of this study was to analyze the ECG time intervals in the course of the development of chronic anthracycline cardiomyopathy in rabbits. Furthermore, this approach was employed to study the effects of a model cardioprotective drug (dexrazoxane) and two novel iron chelating compounds - salicylaldehyde isonicotinoyl hydrazone (SIH) and pyridoxal 2-chlorobenzoyl hydrazone (o-108). Repeated daunorubicin administration induced a significant and progressive prolongation of the QRS complex commencing with the 8th week of administration. At the end of the study, we identified a significant correlation between QRS duration and the contractility index dP/dtmax (r = -0.81; P<0.001) as well as with the plasma concentrations of cardiac troponin T (r = 0.78; P<0.001). In contrast, no alterations in ECG time intervals were revealed in the groups co-treated with either dexrazoxane or both novel cardioprotective drugs (SIH, o- 108). Hence, in this study, the QRS duration is for the first time shown as a parameter suitable for the non-invasive evaluation of the anthracycline cardiotoxicity and cardioprotective effects of both well established and investigated drugs. Moreover, our results strongly suggest that novel iron chelators (SIH and o-108) merit further study as promising cardioprotective drugs against anthracycline cardiotoxicity.

Grant č. 0021620820 MSM

Bibliografie atd.

Lit.: 14

000      
03764naa 2200517 a 4500
001      
bmc07502303
003      
CZ-PrNML
005      
20111210121410.0
008      
080305s2007 xr e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Potáčová, Anna. $7 xx0193799
245    10
$a Evaluation of ECG time intervals in a rabbit model of anthracycline-induced cardiomyopathy, a useful tool for assessment of cardioprotective agents / $c Anna Potáčová, Michaela Adamcová, H. Čajnáková, L. Hrbatová, Martin Štěrba, Olga Popelová, Tomáš Šimůnek, Přemysl Poňka, Vladimír Geršl
314    __
$a Faculty of Medicine, Charles University, Hradec Králové
500    __
$a Grant č. 0021620820 MSM
504    __
$a Lit.: 14
520    9_
$a The aim of this study was to analyze the ECG time intervals in the course of the development of chronic anthracycline cardiomyopathy in rabbits. Furthermore, this approach was employed to study the effects of a model cardioprotective drug (dexrazoxane) and two novel iron chelating compounds - salicylaldehyde isonicotinoyl hydrazone (SIH) and pyridoxal 2-chlorobenzoyl hydrazone (o-108). Repeated daunorubicin administration induced a significant and progressive prolongation of the QRS complex commencing with the 8th week of administration. At the end of the study, we identified a significant correlation between QRS duration and the contractility index dP/dtmax (r = -0.81; P<0.001) as well as with the plasma concentrations of cardiac troponin T (r = 0.78; P<0.001). In contrast, no alterations in ECG time intervals were revealed in the groups co-treated with either dexrazoxane or both novel cardioprotective drugs (SIH, o- 108). Hence, in this study, the QRS duration is for the first time shown as a parameter suitable for the non-invasive evaluation of the anthracycline cardiotoxicity and cardioprotective effects of both well established and investigated drugs. Moreover, our results strongly suggest that novel iron chelators (SIH and o-108) merit further study as promising cardioprotective drugs against anthracycline cardiotoxicity.
650    _2
$a antracykliny $x škodlivé účinky $x terapeutické užití $x toxicita $7 D018943
650    _2
$a daunomycin $x škodlivé účinky $x terapeutické užití $x toxicita $7 D003630
650    _2
$a razoxan $x škodlivé účinky $x terapeutické užití $x toxicita $7 D011929
650    _2
$a chelátory železa $x terapeutické užití $7 D007502
650    _2
$a elektrokardiografie $x využití $7 D004562
650    _2
$a kardiomyopatie $x farmakoterapie $x komplikace $x prevence a kontrola $7 D009202
650    _2
$a troponin $7 D014336
650    _2
$a králíci $7 D011817
650    _2
$a finanční podpora výzkumu jako téma $7 D012109
650    _2
$a zvířata $7 D000818
700    1_
$a Adamcová, Michaela, $d 1964- $7 xx0064762
700    1_
$a Čajnáková, H. $7 _BN002374
700    1_
$a Hrbatová, L. $7 _BN002375
700    1_
$a Štěrba, Martin. $7 xx0076492
700    1_
$a Popelová, Olga. $7 _BN001885
700    1_
$a Šimůnek, Tomáš $7 xx0019029
700    1_
$a Poňka, Přemysl, $d 1941- $7 jk01100569
700    1_
$a Geršl, Vladimír, $d 1946-2015 $7 nlk19990073168
773    0_
$w MED00003824 $t Physiological research $g Roč. 56, č. 2 (2007), s. 251-254 $x 0862-8408
856    41
$u http://www.biomed.cas.cz/physiolres/pdf/56/56_251.pdf $y plný text volně přístupný
910    __
$a ABA008 $b A 4120 $c 266 $y 1
990    __
$a 20080304105411 $b ABA008
991    __
$a 20080305164509 $b ABA008
999    __
$a ok $b bmc $g 617923 $s 470355
BAS    __
$a 3
BMC    __
$a 2007 $b 56 $c 2 $d 251-254 $i 0862-8408 $m Physiological research $x MED00003824
LZP    __
$a 2007-22/mkal

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...